We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Comen Medical

Download Mobile App

World’s First Molecular-Level Analysis of Omicron Spike Protein to Help Develop Variant-Resistant COVID-19 Treatments

By HospiMedica International staff writers
Posted on 27 Dec 2021
Print article
Image: Atomic structure of the Omicron variant spike protein (purple) bound with the human ACE2 receptor (blue) (Photo courtesy of Sriram Subramaniam)
Image: Atomic structure of the Omicron variant spike protein (purple) bound with the human ACE2 receptor (blue) (Photo courtesy of Sriram Subramaniam)

Scientists have unveiled the world’s first molecular-level analysis of the Omicron variant spike protein, revealing strong antibody evasion and binding with human cells that contribute to its increased transmissibility.

Researchers from The University of British Columbia (Vancouver, BC, Canada) have become the first in the world to conduct a molecular-level structural analysis of the Omicron variant spike protein. The analysis—done at near atomic resolution using a cryo-electron microscope—reveals how the heavily mutated variant infects human cells and is highly evasive of immunity. The findings shed new light on why Omicron is highly transmissible and will help accelerate the development of more effective treatments.

The Omicron variant is unprecedented for having 37 spike protein mutations or three to five times more mutations than any other variant seen earlier. This is significant because the spike protein is how the virus attaches to and infects human cells and antibodies attach to the spike protein in order to neutralize the virus. Therefore, small mutations on the spike protein have potentially big implications for how the virus is transmitted, how the human body fights it off, and the effectiveness of treatments.

In order to understand how mutations impact the behavior of the Omicron variant at a molecular level, the scientists conducted a study using cryo-electron microscopy and other tests. The team found that several mutations (R493, S496 and R498) create new salt bridges and hydrogen bonds between the spike protein and the human cell receptor known as ACE2. This appears to increase binding affinity—how strongly the virus attaches to human cells—while other mutations (K417N) decrease the strength of this bond. Overall, the findings showed that Omicron has greater binding affinity than the original SARS-CoV-2 virus, with levels more comparable to those seen with the Delta variant. It is remarkable that the Omicron variant evolved to retain its ability to bind with human cells efficiently despite such extensive mutations.

These findings confirm what is being seen in the real world—that the Omicron spike protein is far better than other variants at evading monoclonal antibodies that are commonly used as treatments, as well as at evading the immunity produced by both vaccines and natural infection.

Notably, Omicron was less evasive of the immunity created by vaccines, as compared to immunity stemming from natural infection in unvaccinated COVID-19 patients. This suggests that vaccination remains the best defiance against the Omicron variant. Both the characteristics seen as a result of spike protein mutations—strong binding with human cells and increased antibody evasion—are likely contributing factors to the increased transmissibility of the Omicron variant. These are the underlying mechanisms fuelling the variant’s rapid spread and why Omicron could become the dominant variant of SARS-CoV-2 very quickly.

However, knowing the molecular structure of the spike protein will now allow researchers to develop more effective treatments against Omicron and related variants in the future. By understanding how the virus attaches to and infects human cells means, researchers can develop treatments that disrupt that process and neutralize the virus. The team is now focusing on improving its understanding of the binding of neutralizing antibodies and treatments that will be effective across the entire range of variants, and how those can be used to develop variant-resistant treatments.

Related Links:
The University of British Columbia 

Print article



view channel

J&J Medical Devices Companies Partners with Microsoft to Further Enable its Digital Surgery Solutions

The Johnson & Johnson Medical Devices Companies (JJMDC; New Brunswick, NJ, USA) will collaborate with Microsoft (Redmond, Wash., USA) to further enable and expand JJMDC’s secure and compliant digital... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.